Verubecestat is a beta-secretase (BACE1) inhibitor investigated for its potential in treating Alzheimer's disease by blocking the production of amyloid-beta peptides. These peptides accumulate in the brains of patients, forming plaques linked to neurodegeneration. By reducing amyloid-beta levels, it was intended to slow disease progression and improve cognitive function. However, phase 3 clinical trials were discontinued in 2017 due to lack of efficacy and adverse effects, including cognitive worsening. It is now primarily used as a research chemical in studies of Alzheimer's pathology and enzyme inhibition.